Telix Pharmaceuticals Financial Ratios
NASDAQ: TLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Telix Pharmaceuticals ratio analysis
Telix Pharmaceuticals earned a net margin of -0.9% in FY 2025, down from 6.5% a year earlier. Gross margin was 53.1% compared with a median of 64.0% over the prior 2 years. Return on equity reached -1.7%, meaning Telix Pharmaceuticals generated -0.02 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.98 versus 1.00 the year before, and the current ratio was 1.43. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Telix Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| P/E ratio (at fiscal year end) | — | 152.97 | — |
| Price / sales | 3.20 | 9.57 | — |
| Price / book | 6.20 | 14.01 | — |
| Gross margin | 53.1% | 65.1% | 62.9% |
| Operating margin | 3.7% | 10.7% | 3.3% |
| Net margin | -0.9% | 6.5% | 1.3% |
| Free cash flow margin | -5.3% | 3.6% | 2.4% |
| Return on equity (ROE) | -1.7% | 9.5% | 4.1% |
| Return on assets (ROA) | -0.6% | 3.6% | 1.5% |
| Debt / equity | 0.98 | 1.00 | 0.06 |
| Current ratio | 1.43 | 2.78 | 1.42 |
| Revenue growth | 55.6% | 55.1% | — |
| EPS growth | -121.6% | 650.8% | — |